Historical Valuation
GRAND PHARMA (00512) is now in the Fair zone, suggesting that its current forward PE ratio of 12.79 is considered Fairly compared with the five-year average of 9.04. The fair price of GRAND PHARMA (00512) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：7.91
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
GRAND PHARMA (00512) has a current Price-to-Book (P/B) ratio of 1.63. Compared to its 3-year average P/B ratio of 1.20 , the current P/B ratio is approximately 35.74% higher. Relative to its 5-year average P/B ratio of 1.34, the current P/B ratio is about 21.95% higher. GRAND PHARMA (00512) has a Forward Free Cash Flow (FCF) yield of approximately 4.34%. Compared to its 3-year average FCF yield of 7.88%, the current FCF yield is approximately -44.88% lower. Relative to its 5-year average FCF yield of 7.86% , the current FCF yield is about -44.79% lower.
Performance Decomposition
AI Analysis
1Y
3Y
5Y
Market capitalization of 00512 increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of 00512 in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is 00512 currently overvalued or undervalued?
GRAND PHARMA (00512) is now in the Fair zone, suggesting that its current forward PE ratio of 12.79 is considered Fairly compared with the five-year average of 9.04. The fair price of GRAND PHARMA (00512) is between to according to relative valuation methord.
What is GRAND PHARMA (00512) fair value?
00512's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of GRAND PHARMA (00512) is between to according to relative valuation methord.
How does 00512's valuation metrics compare to the industry average?
The average P/S ratio for 00512's competitors is , providing a benchmark for relative valuation. GRAND PHARMA Corp (00512) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for GRAND PHARMA (00512) as of Jan 16 2026?
As of Jan 16 2026, GRAND PHARMA (00512) has a P/B ratio of 1.63. This indicates that the market values 00512 at 1.63 times its book value.
What is the current FCF Yield for GRAND PHARMA (00512) as of Jan 16 2026?
As of Jan 16 2026, GRAND PHARMA (00512) has a FCF Yield of 4.34%. This means that for every dollar of GRAND PHARMA’s market capitalization, the company generates 4.34 cents in free cash flow.
What is the current Forward P/E ratio for GRAND PHARMA (00512) as of Jan 16 2026?
As of Jan 16 2026, GRAND PHARMA (00512) has a Forward P/E ratio of 12.79. This means the market is willing to pay $12.79 for every dollar of GRAND PHARMA’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for GRAND PHARMA (00512) as of Jan 16 2026?
As of Jan 16 2026, GRAND PHARMA (00512) has a Forward P/S ratio of 2.17. This means the market is valuing 00512 at $2.17 for every dollar of expected revenue over the next 12 months.